Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the sale, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Patrick O’day also recently made the following trade(s):
- On Tuesday, April 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00.
Gilead Sciences Stock Up 0.1%
Shares of GILD stock opened at $129.18 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29. The firm’s fifty day moving average price is $134.56 and its two-hundred day moving average price is $134.34. The firm has a market capitalization of $160.39 billion, a P/E ratio of 17.60 and a beta of 0.31.
Gilead Sciences Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of GILD. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in Gilead Sciences by 52.1% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock valued at $8,713,000 after purchasing an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. boosted its holdings in Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after purchasing an additional 7,168 shares during the period. NewEdge Wealth LLC boosted its holdings in Gilead Sciences by 2.9% in the 3rd quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock valued at $75,962,000 after purchasing an additional 17,284 shares during the period. Nordea Investment Management AB boosted its holdings in Gilead Sciences by 16.5% in the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after purchasing an additional 726,101 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Gilead Sciences by 4.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 161,155 shares of the biopharmaceutical company’s stock valued at $17,888,000 after purchasing an additional 6,680 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.
Gilead Sciences News Roundup
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the company’s inflammation pipeline and adding gamgertamig, a potential first-in-class T cell engager for autoimmune diseases. This can support the stock by broadening long-term growth opportunities. Article Title
- Positive Sentiment: Gilead reported positive Phase 3 IDEAL trial results for Livdelzi in primary biliary cholangitis, including improved ALP normalization, which strengthens the case for a larger liver disease franchise and potential regulatory momentum. Article Title
- Positive Sentiment: Additional coverage highlighted favorable Livdelzi data and the company’s expanding liver and oncology footprint, which may reinforce confidence in Gilead’s growth pipeline. Article Title
- Neutral Sentiment: Coverage also noted that Gilead is drawing investor attention and being compared with other healthcare names, but these articles are more commentary than a direct new catalyst. Article Title
- Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan. While routine, insider selling can still weigh on sentiment for some investors. Article Title
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on GILD shares. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Jefferies Financial Group started coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Finally, The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Twenty-six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $156.93.
Get Our Latest Report on Gilead Sciences
About Gilead Sciences
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Articles
- Five stocks we like better than Gilead Sciences
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
